Carl Zeiss Meditec AG (CHIX:AFXD) Debt-to-Equity: N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AFXD Carl Zeiss Meditec AG CHIX:AFXD
65 GF Score
Price €28.73
GF Value €69.32
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG Debt-to-Equity?

Carl Zeiss Meditec AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0 Mil. Carl Zeiss Meditec AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0 Mil. Carl Zeiss Meditec AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Carl Zeiss Meditec AG's Debt-to-Equity or its related term are showing as below:

CHIX:AFXd' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.05   Max: 0.11
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Carl Zeiss Meditec AG was 0.11. The lowest was 0.00. And the median was 0.05.

CHIX:AFXd's Debt-to-Equity is ranked better than
77.87% of 705 companies
in the Medical Devices & Instruments industry
Industry Median: 0.23 vs CHIX:AFXd: 0.06

Carl Zeiss Meditec AG  (CHIX:AFXd) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Carl Zeiss Meditec AG Debt-to-Equity Related Terms

Carl Zeiss Meditec AG Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG Debt-to-Equity Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.06 0.07 0.07 0.06

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 0.07 N/A 0.06 N/A

CHIX:AFXD vs ISRG, BDX, MDLN: Debt-to-Equity Comparison

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG Debt-to-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's Debt-to-Equity falls into.


CHIX:AFXD
65GF Score
Carl Zeiss Meditec AG CHIX:AFXD
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Carl Zeiss Meditec AG's Debt to Equity Ratio for the fiscal year that ended in Sep. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(24.138 + 108.318) / 2116.506
=0.06

Carl Zeiss Meditec AG's Debt to Equity Ratio for the quarter that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Carl Zeiss Meditec AG (CHIX:AFXD) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of €28.73 is trading 58.6% below its estimated GF Value™ of €69.32. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for CHIX:AFXD:

  • Debt-to-Equity: N/A
  • GF Value™: €69.32 vs. price of €28.73 (58.6% below fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the CHIX:AFXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
65GF Score

Get the complete analysis for CHIX:AFXD

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.73
Price
€69.32
GF Value